- Home
- EQH vs KROS Comparison
EQH vs KROS Comparison
Compare EQH & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQH
- KROS
- Stock Information
- Founded
- EQH 1859
- KROS 2015
- Country
- EQH United States
- KROS United States
- Employees
- EQH N/A
- KROS 163
- Industry
- EQH Specialty Insurers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- EQH Finance
- KROS Health Care
- Exchange
- EQH Nasdaq
- KROS Nasdaq
- Market Cap
- EQH N/A
- KROS 558.9M
- IPO Year
- EQH N/A
- KROS 2020
- Fundamental
- Price
- EQH $55.91
- KROS $13.35
- Analyst Decision
- EQH Strong Buy
- KROS Buy
- Analyst Count
- EQH 11
- KROS 13
- Target Price
- EQH $62.45
- KROS $20.63
- AVG Volume (30 Days)
- EQH 2.6M
- KROS 620.1K
- Earning Date
- EQH 07-29-2025
- KROS 08-06-2025
- Dividend Yield
- EQH 1.93%
- KROS N/A
- EPS Growth
- EQH 13.70
- KROS N/A
- EPS
- EQH 3.76
- KROS 0.11
- Revenue
- EQH $15,105,000,000.00
- KROS $214,713,000.00
- Revenue This Year
- EQH $22.89
- KROS $5,006.76
- Revenue Next Year
- EQH $3.86
- KROS N/A
- P/E Ratio
- EQH $14.89
- KROS $123.16
- Revenue Growth
- EQH 45.39
- KROS 91657.70
- 52 Week Low
- EQH $36.46
- KROS $9.12
- 52 Week High
- EQH $56.61
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- EQH 63.19
- KROS 43.06
- Support Level
- EQH $53.72
- KROS $13.41
- Resistance Level
- EQH $54.68
- KROS $13.99
- Average True Range (ATR)
- EQH 1.23
- KROS 0.44
- MACD
- EQH 0.14
- KROS -0.07
- Stochastic Oscillator
- EQH 97.02
- KROS 9.84
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.